The study supports the principle that genetic tests help physicians predict a drug's effect on patients, says Seth Hetherington of GlaxoSmithKline in Research Triangle Park, N.C., who has been conducting related experiments with abacavir. --D.C.
Hyderabad-based pharmaceutical firm Aurobindo Pharma (NSE: AUROPHARMA) announced on Thursday that it had been granted approval from the US Food and Drug Administration (FDA) to manufacture abacavir sulfate and lamivudine tablets, which are used in the treatment of HIV.
* [Abstract 32] Patients with moderate or severe lipoatrophy who were taking either d4T (Zerit[R]) or AZT (Retrovir[R]) were randomly assigned to either continue their treatment, or substitute abacavir (Ziagen[R]) for the d4T or AZT.
In DRIVE-FORWARD, PIFELTRO demonstrated sustained viral suppression through 48 weeks, meeting its primary endpoint of non-inferior efficacy compared to darunavir + ritonavir, each in combination with FTC/TDF or abacavir (ABC)/3TC.
Abacavir sulfate and lamivudine tablets in 600 mg and 300 mg doses is a generic bioequivalent of VIV Healthcare's Epzicom tablets, used to treat HIV-1 infection, while olmesartan medoxomil and hydrochlorothiazide tablets, 20 mg/12.5 mg, 40 mg/12.5 mg and 40 mg/25 mg, have been judged therapeutically equivalent to Daiichi Sankyo Ltd.'s Benicar HCT, which is used to treat hypertension.